Today: 4 February 2026
Subscribe
Browse Category

NASDAQ:BMEA News 5 December 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s…
5 December 2025
····

Stock Market Today

  • Novo Nordisk Shares Drop Amid Price Cuts; Eli Lilly's Mounjaro Soars
    February 4, 2026, 10:42 AM EST. Shares of Danish weight loss drug maker Novo Nordisk plunged nearly 20% after it warned of a 5-13% decline in sales and earnings this year due to price cuts and mounting competition. The firm's CEO Mike Doustdar highlighted pricing pressures, despite launching a new Wegovy pill in the U.S. In contrast, rival Eli Lilly reported doubling of pre-tax earnings to $25.73 billion and a 110% surge in sales of its Mounjaro drug in the last quarter of 2025. Lilly forecasts revenue growth to $80-83 billion in 2026. Analysts note Eli Lilly is capturing market share as pricing dips and competition intensify for Novo Nordisk. The companies also face pressure from a U.S. agreement to reduce drug prices and expand insurer access.
Go toTop